ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.861,50
1,97%
S&P 500
6.012,28
-1,46%
US Dollar vs BRL
5,8935
-0,01%
Bitcoin
102.759,00
0,68%
Brent Oil
76,625
0,47%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Cartesian Therapeutics Inc (RNAC)

  7. Cartesian Therapeutics Inc (RNAC) Notícias

RNAC

Cartesian Therapeutics (RNAC)

Cartesian Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RNAC
DataHoraFonteTítuloCódigoCompanhia
27/01/202509:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNACCartesian Therapeutics Inc
27/01/202509:00GlobeNewswire Inc.Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia GravisNASDAQ:RNACCartesian Therapeutics Inc
14/01/202502:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNACCartesian Therapeutics Inc
13/01/202518:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNACCartesian Therapeutics Inc
13/01/202509:00GlobeNewswire Inc.Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune DiseasesNASDAQ:RNACCartesian Therapeutics Inc
10/01/202508:01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:RNACCartesian Therapeutics Inc
08/01/202518:38Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RNACCartesian Therapeutics Inc
08/01/202518:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RNACCartesian Therapeutics Inc
07/01/202509:05GlobeNewswire Inc.Cartesian Therapeutics Announces New Employment Inducement GrantsNASDAQ:RNACCartesian Therapeutics Inc
13/12/202418:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RNACCartesian Therapeutics Inc
10/12/202418:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNACCartesian Therapeutics Inc
03/12/202408:00GlobeNewswire Inc.Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 TrialNASDAQ:RNACCartesian Therapeutics Inc
21/11/202409:00GlobeNewswire Inc.Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease SummitNASDAQ:RNACCartesian Therapeutics Inc
07/11/202409:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RNACCartesian Therapeutics Inc
07/11/202409:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNACCartesian Therapeutics Inc
07/11/202409:00GlobeNewswire Inc.Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:RNACCartesian Therapeutics Inc
05/11/202411:00GlobeNewswire Inc.Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual MeetingNASDAQ:RNACCartesian Therapeutics Inc
15/10/202417:30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:RNACCartesian Therapeutics Inc
15/10/202408:00GlobeNewswire Inc.Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual MeetingNASDAQ:RNACCartesian Therapeutics Inc
09/09/202408:00GlobeNewswire Inc.Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile DermatomyositisNASDAQ:RNACCartesian Therapeutics Inc
06/09/202408:05GlobeNewswire Inc.Cartesian Therapeutics Announces New Employment Inducement GrantNASDAQ:RNACCartesian Therapeutics Inc
03/09/202408:00GlobeNewswire Inc.Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15NASDAQ:RNACCartesian Therapeutics Inc
26/08/202408:00GlobeNewswire Inc.Cartesian Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:RNACCartesian Therapeutics Inc
08/08/202408:00GlobeNewswire Inc.Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:RNACCartesian Therapeutics Inc
02/07/202417:05GlobeNewswire Inc.Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal MalikNASDAQ:RNACCartesian Therapeutics Inc
02/07/202407:31GlobeNewswire Inc.Cartesian Therapeutics Announces $130 Million Private Placement Equity FinancingNASDAQ:RNACCartesian Therapeutics Inc
02/07/202407:31GlobeNewswire Inc.Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus ErythematosusNASDAQ:RNACCartesian Therapeutics Inc
02/07/202407:30GlobeNewswire Inc.Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia GravisNASDAQ:RNACCartesian Therapeutics Inc
22/05/202408:00GlobeNewswire Inc.Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia GravisNASDAQ:RNACCartesian Therapeutics Inc
13/05/202417:30GlobeNewswire Inc.Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:RNACCartesian Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RNAC

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
AMER3
Americanas ON
BOV
PMAM3
PARANAPANEMA ON
BOV
YDUQ3
ESTACIO PART ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados